MedTrace Logo

The McGill RAAS-COVID-19 Trial

NCT04508985 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-08-07

No results posted yet for this study

Summary

Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases may increase the ability of COVID-19 to infect cells. The RAAS-COVID-19 trial aims to assess whether temporarily holding these CV drugs in patients who are admitted with COVID-19, versus continuing them, in patients admitted with COVID-19 can impact short term outcomes.

Conditions

Interventions

OTHER

Temporarily holding the RAAS inhibitor [intervention]

Temporarily holding the RAAS inhibitor. Among participants who will be randomized to the intervention arm, a possible guideline-directed alternative to anti-hypertensive medication alternatives will be provided to the treating physician team.

OTHER

RAAS inhibitor [continued standard of care]

No intervention, Continuation RAAS inhibitor \[continued standard of care\].

Sponsors & Collaborators

  • Jewish General Hospital (Montreal, Quebec, Canada)

    collaborator UNKNOWN

  • Montreal General Hospital (Montreal, Quebec, Canada)

    collaborator UNKNOWN

  • Université de Lorraine, Centre d'Investigation Clinique- Plurithématique Inserm

    collaborator UNKNOWN

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Abhinav Sharma, MD · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-04-01
Completion
2021-04-17

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04508985 on ClinicalTrials.gov